ABSTRACT
Objective:To screen out and analyze the key genes of follicular lymphoma (FL) according to transcriptome data in Gene Expression Omnibus (GEO) database.Methods:Transcriptome datasets GSE32018 and GSE55267 were collected by using GEO database. R software was used for variance analysis to screen differentially expressed genes. FunRich 3.13 software was used to analyze common differential genes. The biological processes and pathways were analyzed with Cytoscape 3.7.2 software to screen potential genes related to the pathogenesis of FL. By analyzing clinical data from Oncomine database for survival analysis, the screened differential genes were verified.Results:A total of 141 up-regulated genes and 199 down-regulated genes were identified by differentially analyzing GSE32018 and GSE55267 datasets. Finally, 12 key genes including CXCL8, KRT19, CYCS, CDKN3, SFN, RRM2, FN1, APOE, CXCL12, VWF, GATA3 and TIMP1 were screened out; CYCS, CXCL8 and CXCL12 were closely related with the early survival rate of patients. Overexpression of CXCL12 and low expression of CYCS were found to be associated with poor prognosis of FL patients. CXCL8 expression was decreased in lymphoma tissues, but the relatively high expression of CXCL8 in survival analysis showed shortened overall survival, which might be related to the early development of FL. GO, KEGG and Reactome pathways were screened out including GO: 0001892, KEGG: 04115, R-HSA: 2559582, GO: 0060968, R-HSA: 6785807, GO: 0043627, GO: 0001936 and GO: 0043062.Conclusion:The selected genes CYCS, CXCL8 and CXCL12 may provide more effective biomarkers for the treatment of FL.
ABSTRACT
Objective To compare the advanced non -small cell lung cancer (NSCLC)patients before and after chemotherapy peripheral blood EGFR mutation status,we understand whether the chemotherapy drug impacts the EGFR mutation status of the advanced NSCLC patients,so as to improve the precision of EGFR TKIs -drug use. Methods To collect the peripheral blood of 30 cases of advanced NSCLC before chemotherapy and after chemotherapy for 6 cycles.DHPLC technique was used to detect the EGFR mutation states of EGFR exon 19 and in exon 21.Results In 30 patients,chemotherapy prior EGFR mutation positive rate was 53.3% (16 /30).After 6 cycles of chemotherapy, the EGFR mutation positive rate was 36.6% (11 /30),the consistent rate was 56.6 (17 /30)before and after chemo-therapy,inconsistent rate was 53.4% (13 /30).10 cases from positive to negative before chemotherapy,3 cases from negative into positive before chemotherapy with statistical significance (P =0.046).Six EGFR19 exons changed, change rate of 20%,8 EGFR21 exons shift changed at a rate of 26%.EGFR19,21 shift in 1 case,with no statistical significance(P =0.39,P >0.05).Conclusion (1)The late NSCLC patients before and after peripheral blood of EGFR mutation status change,so before starting the targeted therapy we must recive real -time detection of peripheral blood EGFR mutation status,so as to decide whether to choose EGFR TKIs targeted drug therapy.(2)EGFR21 exons transformation rate is higher than EGFR19 exons conversion rate,but with no statistical difference,this phenomenon may be related to EGFR19 exons patients who with EGFR mutations -TKIs treatment efficiency is higher.
ABSTRACT
Objective To develop a HPLC method for the determination of chlorogenic acid in xiaoaiping injection in human plasma.Methods The analytical column was packed with Hypersil ODS C18 (250 mm×4.6 nm,5 μm).The mobile phase was acetonitrile-0.4% phosphoric acid solution(13:87).The flow rate was 1 ml/min,and detection wave length was set at 327 nm.Results The linear ranges were 2.5～60.0 mg/L chlorogenic acid in human plasma,with the correlation coefficients of 0.9996.The Low limit of detection was 0.25 μg/ml.The method and extraction recovery were 100.1%～102.6%and 78.6%～80.3%.The relative standard deviation value for the within-day and between-day precision were less than 3.9%.Conclusion The method is simple,sensitive for the determination of chlorogenic acid in xiaoaiping injection in human plasma.